Section
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
This article explores a novel, biologically informed framework for monitoring transthyretin amyloid cardiomyopathy progression and treatment, emphasizing mechanism-specific strategies aimed at personalized care.
This multicenter study reveals improved outcomes in fetal cardiomyopathy, highlights genetic underpinnings in one-third of cases, and identifies fetal hydrops and extracardiac anomalies as key prenatal risk factors for mortality.
Vutrisiran, an RNA interference therapeutic, significantly improves cardiac function, reduces amyloid burden, and attenuates disease progression in transthyretin amyloid cardiomyopathy as revealed by multiparametric cardiovascular MRI and c
This analysis reveals that waist circumference and waist-to-hip ratio improve cardiovascular risk classification beyond BMI, identifying individuals with hidden risk and refining prognostic assessments across multiple cardiovascular outcome
This study identifies pre-transplant left atrial volume index as a potential predictor for overall one-year morbidity following kidney transplantation, highlighting its clinical relevance beyond traditional cardiac risk markers.
A large UK cohort study reveals that beta-blockers reduce mortality in COPD patients with heart failure or ischemic heart disease, but concurrent long-acting beta-agonists may attenuate this benefit.
This article explores the unique genomic and transcriptomic features of hepatocellular carcinoma in Fontan-associated liver disease, revealing distinct mutation patterns and poor-prognosis molecular subtypes that inform disease mechanisms a
This study explores the potential of an AI-powered ECG tool to monitor left ventricular systolic dysfunction in hypertrophic cardiomyopathy patients treated with mavacamten, offering a less burdensome alternative to frequent echocardiograms
This article explores the high prevalence of heart failure with preserved ejection fraction (HFpEF) in adults with congenital heart disease (ACHD), highlighting its clinical features, hospitalization burden, and under-treatment issues.
Sotatercept improves exercise tolerance in pulmonary arterial hypertension through pulmonary vascular remodeling, systemic decongestion with hemoconcentration, improved right ventricular-pulmonary artery coupling, enhanced cardiac output re
A pioneering study shows that AI-enhanced ECG screening combined with epidemiological data can identify undiagnosed Chagas disease cases, improving early detection and care in endemic Brazil.
This review synthesizes evidence on physician-focused financial incentives for hypertension control, highlighting nuanced impacts on clinical decisions, documented blood pressure control, and cardiovascular outcomes, with a focus on both ov
This study evaluates the real-world effectiveness and safety of direct oral anticoagulants versus warfarin in Asian patients with atrial fibrillation and mitral stenosis, revealing higher stroke yet lower myocardial infarction risk with DOA
The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico
A randomized trial shows reperfusion-guided blood pressure management post-thrombectomy improves functional outcomes and reduces hemorrhagic transformation, supporting personalized BP targets based on reperfusion status.
Elevated endogenous insulin and insulin resistance independently predict progression of diastolic dysfunction and increased cardiovascular mortality, highlighting early metabolic dysregulation as a target to prevent heart failure with prese
This review synthesizes recent evidence on adult subvalvular aortic stenosis, highlighting long-term clinical outcomes, disease progression, and implications for management and follow-up strategy.
This phase 3 trial demonstrates that the oral PCSK9 inhibitor enlicitide achieves significantly greater LDL-C reduction than bempedoic acid, ezetimibe, or their combination in statin-treated adults at elevated cardiovascular risk, with comp
This study reveals that two-thirds of community sudden cardiac deaths occur in individuals without diagnosed cardiac disease, with half harboring occult myocardial infarction or dilated cardiomyopathy, underscoring the need for improved det
